Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-time margin assessment in head and neck cancer using cetuximab-800CW fluorescence imaging
2022-002779-12Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab-IRDye 800CW in head and neck cancer (HNC) and Oral Mucosal Carcinoma, sponsored by University Medical Center Groningen. Primary endpoint: Macroscopic fluorescent signals on the excised tissue specimen and tracer distribution observed with fluorescence imaging. Started Oct 2022; status: active.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
head and neck cancer (HNC)Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2022-002779-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002779-12.